Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives

Title: Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives

Volume: 9 Issue: 7

Author(s): Sante Cundari and Guido Cavaletti

Affiliation:

Keywords: IMiDs, thalidomide, CC-5013, lenalidomide, CC-4047, pomalidomide, safety, side effects, CIPN

Abstract: IMiDs compounds are a class of analogues of thalidomide, with greater immunomodulatory activity and a superior safety profile compared to the parent compound. They show substantial increase in potency and an interesting tolerability profile, primarily due to a decreased incidence of the most severe side effect of thalidomide, i.e. Chemotherapy- Induced Peripheral Neurotoxicity (CIPN). These novel aspects of the IMiDs compounds will be discussed.

Cite this article as:

Cundari Sante and Cavaletti Guido, Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives, Mini-Reviews in Medicinal Chemistry 2009; 9 (7) . https://dx.doi.org/10.2174/138955709788452595